Promoted Content
Promoted Content

Find Clinical Drug Pipelines for Sleep

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Reboxetine

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Axsome Therapeutics

            Deal Size: $331.0 million Upfront Cash: $3.0 million

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia

            Virtual BoothTransforming oral delivery challenges into proprietary product solutions.

            Contact the Supplier

            Lead Product(s): Mazindol

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NLS Pharmaceutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 13, 2020

            Details:

            NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aroxybutynin,Atomoxetine Hydrochloride

            Therapeutic Area: Sleep Product Name: AD109

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            First patient has been dosed in first Phase 2 clinical trial evaluating AD109, the company’s first-in-class, oral pharmaceutical under development for the treatment of OSA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pitolisant

            Therapeutic Area: Sleep Product Name: Wakix

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Citrine Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 28, 2020

            Details:

            The partnership provides Citrine with exclusive rights to develop, register, market, and manufacture Wakix® (pitolisant) in China for the treatment of narcolepsy and obstructive sleep apnea.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daridorexant

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $592.3 million Upfront Cash: Undisclosed

            Deal Type: Financing October 21, 2020

            Details:

            The increased liquidity will be used to prepare for the launch of daridorexant and further fund Idorsia’s diversified pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcium,Magnesium,Potassium

            Therapeutic Area: Sleep Product Name: Xywav

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            Xywav demonstrated highly statistically significant differences in median change in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pitolisant

            Therapeutic Area: Sleep Product Name: Wakix

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            WAKIX is the first and only non-scheduled treatment approved for excessive daytime sleepiness or cataplexy in adult patients with narcolepsy .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Calcium,Magnesium,Potassium

            Therapeutic Area: Sleep Product Name: Xywav

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            All patients were treated with Xywav during the open-label titration period and clinically meaningful improvements in the Epworth Sleepiness Scale (ESS) were observed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daridorexant

            Therapeutic Area: Sleep Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $632.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 08, 2020

            Details:

            The proceeds from the offering will be used to support the regulatory filing and, if approved, commercial launch of daridorexant and to fund the further development of its diversified pipeline.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Melatonin,Chamomile

            Therapeutic Area: Sleep Product Name: Kinderlyte Sleep

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            Kinderlyte's Herbal Sleep Supplement is a doctor-formulated, drug-free sleep aid that uses a proprietary blend of melatonin and calming botanicals such as chamomile, passionflower, and lemon balm to support sleep.

            PharmaCompass